Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C12H22O11 |
Molecular Weight | 342.2965 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)([C@H](O)CO)[C@H](O)C(=O)CO
InChI
InChIKey=PFCRQPBOOFTZGQ-VZXVHDRGSA-N
InChI=1S/C12H22O11/c13-1-4(16)7(18)11(5(17)2-14)23-12-10(21)9(20)8(19)6(3-15)22-12/h5-15,17-21H,1-3H2/t5-,6-,7-,8+,9+,10-,11-,12+/m1/s1
DescriptionSources: https://www.drugs.com/mtm/lactulose.html
Sources: https://www.drugs.com/mtm/lactulose.html
Lactulose is a non-absorbable sugar used in the treatment of constipation and hepatic encephalopathy. It is a disaccharide (double-sugar) formed from one molecule each of the simple sugars (monosaccharides) fructose and galactose. Lactulose is not normally present in raw milk but is a product of heat-processed: the greater the heat, the greater amount of this substance. Lactulose is not absorbed in the small intestine nor broken down by human enzymes, thus stays in the digestive bolus through most of its course, causing retention of water through osmosis leading to softer, easier to pass stool. It has a secondary laxative effect in the colon, where it is fermented by the gut flora, producing metabolites which have osmotic powers and peristalsis-stimulating effects (such as acetate), but also methane associated with flatulence. Lactulose is metabolized in the colon by bacterial flora to short chain fatty acids including lactic acid and acetic acid. These partially dissociate, acidifying the colonic contents (increasing the H+ concentration in the gut).[14] This favors the formation of the nonabsorbable NH+4 from NH3, trapping NH3 in the colon and effectively reducing plasma NH3 concentrations. Lactulose is used in the treatment of chronic constipation in patients of all ages as a long-term treatment. Lactulose is used for chronic idiopathic constipation, i.e. chronic constipation occurring without any identifiable cause. Lactulose may be used to counter the constipating effects of opioids, and in the symptomatic treatment of hemorrhoids as a stool softener.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0015696 Sources: https://www.drugs.com/pro/lactulose.html |
|||
Target ID: GO:0015696 Sources: https://www.drugs.com/pro/lactulose.html |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CEPHULAC Approved UseFor the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Controlled studies have shown that lactulose solution therapy reduces the blood ammonia levels by 25-50%; this is generally paralleled by an improvement in the patients' mental state and by an improvement in EEG patterns. The clinical response has been observed in about 75% of patients, which is at least as satisfactory as that resulting from neomycin therapy. An increase in patients' protein tolerance is also frequently observed with lactulose therapy. In the treatment of chronic portal-systemic encephalopathy, Lactulose has been given for over 2 years in controlled studies. Launch Date1976 |
|||
Primary | CEPHULAC Approved UseFor the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Controlled studies have shown that lactulose solution therapy reduces the blood ammonia levels by 25-50%; this is generally paralleled by an improvement in the patients' mental state and by an improvement in EEG patterns. The clinical response has been observed in about 75% of patients, which is at least as satisfactory as that resulting from neomycin therapy. An increase in patients' protein tolerance is also frequently observed with lactulose therapy. In the treatment of chronic portal-systemic encephalopathy, Lactulose has been given for over 2 years in controlled studies. Launch Date1976 |
PubMed
Title | Date | PubMed |
---|---|---|
The effect of antenatal vitamin A and beta-carotene supplementation on gut integrity of infants of HIV-infected South African women. | 2001 Apr |
|
Clostridial constipation's broad pathology. | 2001 Apr |
|
Lactose malabsorption and intolerance in the elderly. | 2001 Dec |
|
Use of an orally administered combined sugar solution to evaluate intestinal absorption and permeability in cats. | 2001 Jan |
|
[Intestinal permeability in Crohn's disease and effects of elemental dietary therapy]. | 2001 Jun |
|
Lactulose may help prevent urinary tract infections. | 2001 Oct 20 |
|
Typhoid, hepatitis E, or typhoid and hepatitis E: the cause of fulminant hepatic failure--a diagnostic dilemma. | 2002 Feb |
|
Small intestinal bacterial overgrowth, intestinal permeability, and non-alcoholic steatohepatitis. | 2002 Jan |
|
Evaluation of hydrogen excretion after lactulose administration as a screening test for causes of irritable bowel syndrome. | 2002 Jul |
|
The relationships between intestinal damage and circulating endotoxins in experimental Trypanosoma brucei brucei infections. | 2002 Jun |
|
[Hepatic encephalopathy after TIPS--retrospective study]. | 2002 May |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/lactulose.html#DA
The usual adult, oral dosage is 2 to 3 tablespoonfuls (30 mL to 45 mL, containing 20 grams to 30 grams of Lactulose) three or four times daily. The dosage may be adjusted every day or two to produce 2 or 3 soft stools daily.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QA06AD11
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
||
|
LOINC |
74900-2
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
||
|
WHO-ATC |
A06AD61
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
||
|
NCI_THESAURUS |
C68472
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
||
|
WHO-ATC |
A06AD11
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
||
|
NDF-RT |
N0000175811
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
||
|
NCI_THESAURUS |
C29697
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.4
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
||
|
WHO-VATC |
QA06AD61
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
||
|
LOINC |
74899-6
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6218
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
PRIMARY | RxNorm | ||
|
C29148
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
PRIMARY | |||
|
2137
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
PRIMARY | |||
|
DTXSID5045833
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
PRIMARY | |||
|
1536
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
PRIMARY | |||
|
SUB08386MIG
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
PRIMARY | |||
|
3037557
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
PRIMARY | PUBCHEM | ||
|
D007792
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
PRIMARY | |||
|
m6665
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB00581
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
PRIMARY | |||
|
757082
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
PRIMARY | |||
|
6359
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
PRIMARY | |||
|
100000091634
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
PRIMARY | |||
|
9U7D5QH5AE
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
PRIMARY | |||
|
225-027-7
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
PRIMARY | |||
|
9U7D5QH5AE
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
PRIMARY | |||
|
LACTULOSE
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
PRIMARY | |||
|
1356803
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
PRIMARY | |||
|
SUB12100MIG
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
ALTERNATIVE | |||
|
CHEMBL296306
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
PRIMARY | |||
|
4618-18-2
Created by
admin on Sat Dec 16 18:25:25 GMT 2023 , Edited by admin on Sat Dec 16 18:25:25 GMT 2023
|
PRIMARY |
ACTIVE MOIETY